Shield Therapeutics Share Discussion Threads

[bolitix] 19/12/2023 15:07

It really does not matter what the rest of the worlds sales do. They know the US lates sales are actually 36% down pro-rata on the 22 sales team they had 4Q22 and this CEO pitiful upbeat sales pitch, even though prescriber access went up nearly 4 fold, is typical reason on his watch this share price demise from 56p on his take-over. Hence, until we get rid of this clowns's agenda to drain salaries out of the share rather than pursue profit this share price will simply struggle.

[skcots48] 19/12/2023 09:53

Standard regulatory approval time in Canada is 1 year from submissionI think they have a problem. It should have come through in the July timeframeI've just done a search on the Health Canada database and no sign of a decision. So I think they must be appealing or providing additional supporting information Big picture, I don't think it actually matters, Canada sales are irrelevant v the US. I know they all add up but even so the only other one that really matters is China

[olosnahjames] 19/12/2023 08:50

News from Canada is long overdue. It was originally marked for H1 2023. I don’t understand the delay. A China update on the new ‘expected̵7; trial completion and approval would also be nice.

[cyberbub] 18/12/2023 10:57

Someone is definitely still selling out IMO. Could take weeks to clear them, but some good news will help to increase volume and get them out faster.

[z1co] 14/12/2023 18:29

Q3 sales of $4.1m were well above the brokers forecasts of $3.6m

[z1co] 14/12/2023 18:27

Shield Therapeutics is "bearing fruit", says Cavendish

Published: 16:05 13 Dec 2023 GMT

Shield Therapeutics PLC - Shield Therapeutics is "bearing fruit", says Cavendish

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s third-quarter trading update for Accrufer in the US market shows its tie-up with Viatris and expanded sales team are “bearing fruit”, according to analysts.

Accrufer is a non-salt based oral therapy used to treat iron deficiency in adults.

Analysts at Cavendish said key performance indicators such as total scrips, new scrips, retention rate, and net realised price are all showing significant improvement compared to the first half of 2023.

The number of US representatives promoting Accrufer increased from 16 to 30 in the first quarter of 2023, and by May 2023, a total of 100 had been trained to sell the product.

Third quarter unaudited sales were US$4.1 million, above the broker’s forecasts of US$3.6 million, and the company said trading is in-line with expectations.

[bolitix] 12/12/2023 15:10

Wherever would you get a share that was once over £1.80 based on a US prospect sitting at 6.6p once its US prospect is being realized - end of year figures will show a 70%+ yr on yr gain!!

[cyberbub] 11/12/2023 22:44

There always need to be sellers or else the MMs will not let anyone buy. MMs won't risk going short on a stock like this. I'm encouraged that the selling was fairly limited, no obvious big 1M seller, touch wood! GLA

[eringael] 11/12/2023 17:47

Seller / sellers not done yet sadly

[r9505571] 11/12/2023 17:08

The analyst consensus target price for shares in Shield Therapeutics is 36.67p. That is 486.72% above the last closing price of 6.25p.https://www.stockopedia.com › shie...Shield Therapeutics Share Price - LON:STX Stock Research - Stockopedia

[the imperialist] 11/12/2023 15:40

The train is leaving the station. 13p target for me.

[cyberbub] 11/12/2023 15:18

Lots of buying at full offer. There may be another delayed sell published later? Good news if it's being overwhelmed...

[devonlad] 11/12/2023 14:43

yup, breakout from the recent trading range should take us to the 10/12p area again now.

[z1co] 11/12/2023 14:22

Looks like the seller is done for now hence the rise.

[cyberbub] 11/12/2023 14:20

I agree that it might take until the Q1 or even Q2 2024 figures to be certain that the company has achieved full sales traction into profitability. But Mr Market looks ahead, and I think that the Q3 figures just published provide a decent speculation that we're on track for that. Based on the share price action, Mr Market seems to agree...GLA

[the imperialist] 11/12/2023 14:11

Whoosh time. Same old MO. Delayed reaction, avoid the hot money. Bodes well.

[z1co] 11/12/2023 12:09

His quote " 6 figures invested ".

And yet his posts of bearish nature ! what a pathetic lie , has no shame.

Another few quarters of impressive growth will see the share price reach double figures again.

[the imperialist] 11/12/2023 09:31

Nice language, shame about the grammar.

[wallywoo] 11/12/2023 09:05

Another 2 months of absolutely no investment progress here. Meanwhile stx are busily spending shareholders money. Around 500 ramping posts in that time on the other thread. Most either bullying cynic's off the BB, or making ridiculous claims stx will make you rich. See you in another 2 months for more of the same!! This remains a very good example of a professionally ramped share. Ramped by the same poster's every day (who mostly post nowhere else). Be very careful here

[cyberbub] 11/12/2023 08:50

Good volume today so far

[the imperialist] 11/12/2023 07:46

I totally agree. The mark of a newbie.